Medline Inc. faces securities investigation following FDA warnings

Medline Inc. is facing a potential securities law investigation by the law firm Kaplan Fox & Kilsheimer LLP following regulatory scrutiny. The investigation follows a May 2026 FDA warning letter regarding significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals.

The FDA cited the company for failing to investigate unexplained discrepancies in drug batches and for inadequate cleaning practices and microbial contamination incidents. These regulatory issues previously contributed to a 7.16% drop in Medline stock price in June 2026.

In recent trading activity, major shareholder Private Ltd Gic has executed several large-scale stock sales throughout August 2026. These transactions include a sale of 1,500,000 shares on August 13th and another 100,000 shares on August 14th, both at an average price of $35.80. These sales follow a series of other divestments by the same shareholder earlier in the month.